Search Results
Neil Portman
Neil Portman
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Neil Portman in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Neil Portman in
Google Scholar
PubMed
Sarah Alexandrou
Sarah Alexandrou
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Sarah Alexandrou in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Sarah Alexandrou in
Google Scholar
PubMed
Emma Carson
Emma Carson
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Emma Carson in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Emma Carson in
Google Scholar
PubMed
Shudong Wang
Shudong Wang
Centre for Drug Discovery and Development, Cancer Research Institute, University of South Australia, Adelaide, South Australia, Australia
Search for other papers by Shudong Wang in
Google Scholar
PubMed
Search for other papers by Shudong Wang in
Google Scholar
PubMed
Elgene Lim
Elgene Lim
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Elgene Lim in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by Elgene Lim in
Google Scholar
PubMed
C Elizabeth Caldon
C Elizabeth Caldon
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by C Elizabeth Caldon in
Google Scholar
PubMed
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia
Search for other papers by C Elizabeth Caldon in
Google Scholar
PubMed
controlled by the retinoblastoma (Rb) protein. Rb restricts progression from G 1 phase into S phase by binding and suppressing E2F transcription factors. This is overcome by cyclin-dependent kinase 4/6 (CDK4/6) phosphorylation of the Rb protein, which leads
Kristen Wong
Kristen Wong
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Kristen Wong in
Google Scholar
PubMed
Search for other papers by Kristen Wong in
Google Scholar
PubMed
Francesca Di Cristofano
Francesca Di Cristofano
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Francesca Di Cristofano in
Google Scholar
PubMed
Search for other papers by Francesca Di Cristofano in
Google Scholar
PubMed
Michela Ranieri
Michela Ranieri
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Michela Ranieri in
Google Scholar
PubMed
Search for other papers by Michela Ranieri in
Google Scholar
PubMed
Daniela De Martino
Daniela De Martino
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Daniela De Martino in
Google Scholar
PubMed
Search for other papers by Daniela De Martino in
Google Scholar
PubMed
Antonio Di Cristofano
Antonio Di Cristofano
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Antonio Di Cristofano in
Google Scholar
PubMed
Search for other papers by Antonio Di Cristofano in
Google Scholar
PubMed
the cell cycle into the S phase is controlled by complexes formed by D-type cyclins and the CDK4 and CDK6 kinases, which phosphorylate and inactivate the RB tumor suppressor. In turn, RB inactivation releases the E2F transcription factors to promote
Thomas Yang Sun
Thomas Yang Sun
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Search for other papers by Thomas Yang Sun in
Google Scholar
PubMed
Search for other papers by Thomas Yang Sun in
Google Scholar
PubMed
Lan Zhao
Lan Zhao
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Search for other papers by Lan Zhao in
Google Scholar
PubMed
Search for other papers by Lan Zhao in
Google Scholar
PubMed
Paul Van Hummelen
Paul Van Hummelen
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Search for other papers by Paul Van Hummelen in
Google Scholar
PubMed
Search for other papers by Paul Van Hummelen in
Google Scholar
PubMed
Brock Martin
Brock Martin
Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
Search for other papers by Brock Martin in
Google Scholar
PubMed
Search for other papers by Brock Martin in
Google Scholar
PubMed
Kathleen Hornbacker
Kathleen Hornbacker
Clinical Trials Office, Stanford University, Stanford, California, USA
Search for other papers by Kathleen Hornbacker in
Google Scholar
PubMed
Search for other papers by Kathleen Hornbacker in
Google Scholar
PubMed
HoJoon Lee
HoJoon Lee
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Search for other papers by HoJoon Lee in
Google Scholar
PubMed
Search for other papers by HoJoon Lee in
Google Scholar
PubMed
Li C Xia
Li C Xia
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Division of Biostatistics, Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Li C Xia in
Google Scholar
PubMed
Division of Biostatistics, Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Li C Xia in
Google Scholar
PubMed
Sukhmani K Padda
Sukhmani K Padda
Cedars-Sinai Medical Center, Department of Medical Oncology, Los Angeles, California, USA
Search for other papers by Sukhmani K Padda in
Google Scholar
PubMed
Search for other papers by Sukhmani K Padda in
Google Scholar
PubMed
Hanlee P Ji
Hanlee P Ji
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
Stanford Genome Technology Center, Stanford, California, USA
Search for other papers by Hanlee P Ji in
Google Scholar
PubMed
Stanford Genome Technology Center, Stanford, California, USA
Search for other papers by Hanlee P Ji in
Google Scholar
PubMed
Pamela Kunz
Pamela Kunz
Yale School of Medicine, Smilow Cancer Hospital, Yale Cancer Center, New Haven, Connecticut, USA
Search for other papers by Pamela Kunz in
Google Scholar
PubMed
Search for other papers by Pamela Kunz in
Google Scholar
PubMed
organs with paired clinical outcome data. Our analysis revealed that G3 NENs had gene expression profiles that did not easily segregate by organ, that they shared mutations in TP53 , RB1 , APC , CDKN2A , and in the CDK4/6 cell cycling pathway, and
Meilin Zhang
Meilin Zhang
Department of Burn and Plastic Surgery, Chaoyang Central Hospital, Chaoyang, Liaoning Province, China
Search for other papers by Meilin Zhang in
Google Scholar
PubMed
Search for other papers by Meilin Zhang in
Google Scholar
PubMed
Jian Song
Jian Song
Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning Province, China
Search for other papers by Jian Song in
Google Scholar
PubMed
Search for other papers by Jian Song in
Google Scholar
PubMed
Shigang Guo
Shigang Guo
Department of General Surgery, Chaoyang Central Hospital, Chaoyang, Liaoning Province, China
Search for other papers by Shigang Guo in
Google Scholar
PubMed
Search for other papers by Shigang Guo in
Google Scholar
PubMed
Feng Jin
Feng Jin
Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning Province, China
Search for other papers by Feng Jin in
Google Scholar
PubMed
Search for other papers by Feng Jin in
Google Scholar
PubMed
Ang Zheng
Ang Zheng
Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning Province, China
Search for other papers by Ang Zheng in
Google Scholar
PubMed
Search for other papers by Ang Zheng in
Google Scholar
PubMed
). In recent years, with the continuous innovation of therapies, the emergence of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors has brought new therapeutic directions for HR+, HER2− breast cancer. Globally marketed CDK4/6 inhibitors include
Carol A Lange
Carol A Lange
Departments of Medicine and Pharmacology, Masonic Cancer Center, University of Minnesota, 420 Delaware Street South East, MMC 806, Minneapolis Minnesota 55455, USA
Search for other papers by Carol A Lange in
Google Scholar
PubMed
Search for other papers by Carol A Lange in
Google Scholar
PubMed
Douglas Yee
Douglas Yee
Departments of Medicine and Pharmacology, Masonic Cancer Center, University of Minnesota, 420 Delaware Street South East, MMC 806, Minneapolis Minnesota 55455, USA
Search for other papers by Douglas Yee in
Google Scholar
PubMed
Search for other papers by Douglas Yee in
Google Scholar
PubMed
-dependent protein kinases four and six (CDK4/6) important for mediating phospho-RB-induced cell cycle progression at the G1/S boundary or ‘checkpoint’ ( Fig. 1 ). Other well-characterized functions of D-type cyclins include sequestration of cell cycle inhibitors (p
Thomas Ho Lai Yau
Thomas Ho Lai Yau
School of Medicine, University of Nottingham, Derby, UK
Search for other papers by Thomas Ho Lai Yau in
Google Scholar
PubMed
Search for other papers by Thomas Ho Lai Yau in
Google Scholar
PubMed
Kwok-Leung Cheung
Kwok-Leung Cheung
School of Medicine, University of Nottingham, Derby, UK
Search for other papers by Kwok-Leung Cheung in
Google Scholar
PubMed
Search for other papers by Kwok-Leung Cheung in
Google Scholar
PubMed
kinase 4/6 (CDK4/6) Inhibit Palbociclib, ribociclib Tyrosine kinase inhibitor (TKI) Inhibit Dovitinib An ever-growing arsenal of anticancer agents requires knowledge in optimal application for clinicians and patients to make
H H Milioli
H H Milioli
Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by H H Milioli in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by H H Milioli in
Google Scholar
PubMed
S Alexandrou
S Alexandrou
Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
Search for other papers by S Alexandrou in
Google Scholar
PubMed
Search for other papers by S Alexandrou in
Google Scholar
PubMed
E Lim
E Lim
Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by E Lim in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by E Lim in
Google Scholar
PubMed
C E Caldon
C E Caldon
Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by C E Caldon in
Google Scholar
PubMed
St Vincent’s Clinical School, UNSW Sydney, Sydney, New South Wales, Australia
Search for other papers by C E Caldon in
Google Scholar
PubMed
inhibits progression into S phase. During G 1 /S phase, cyclin dependent kinases (CDKs) phosphorylate Rb; first CDK4/6 is activated by cyclin D1, D2, or D3 to phosphorylate Rb, followed by phosphorylation by CDK2 in complex with cyclin E1 or cyclin E2
Chellappagounder Thangavel
Chellappagounder Thangavel
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Chellappagounder Thangavel in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Chellappagounder Thangavel in
Google Scholar
PubMed
Jeffry L Dean
Jeffry L Dean
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Jeffry L Dean in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Jeffry L Dean in
Google Scholar
PubMed
Adam Ertel
Adam Ertel
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Adam Ertel in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Adam Ertel in
Google Scholar
PubMed
Karen E Knudsen
Karen E Knudsen
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Karen E Knudsen in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Karen E Knudsen in
Google Scholar
PubMed
C Marcelo Aldaz
C Marcelo Aldaz
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by C Marcelo Aldaz in
Google Scholar
PubMed
Search for other papers by C Marcelo Aldaz in
Google Scholar
PubMed
Agnieszka K Witkiewicz
Agnieszka K Witkiewicz
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Agnieszka K Witkiewicz in
Google Scholar
PubMed
Search for other papers by Agnieszka K Witkiewicz in
Google Scholar
PubMed
Robert Clarke
Robert Clarke
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Robert Clarke in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Robert Clarke in
Google Scholar
PubMed
Erik S Knudsen
Erik S Knudsen
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Erik S Knudsen in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Pathology, Department of Carcinogenesis, Lombardi Cancer Center, Department of Oncology and Physiology and Biophysics, Philadelphia, Pennsylvania 19107, USA Departments of
Search for other papers by Erik S Knudsen in
Google Scholar
PubMed
of the preclinical and in silico analyses, it was postulated that activation of RB may represent a viable means to re-establish cell cycle inhibition downstream from endocrine therapy. To interrogate this possibility, the CDK4/6-specific inhibitor
Nader Hussein
Nader Hussein
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Nader Hussein in
Google Scholar
PubMed
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Nader Hussein in
Google Scholar
PubMed
JieLi Lu
JieLi Lu
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by JieLi Lu in
Google Scholar
PubMed
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by JieLi Lu in
Google Scholar
PubMed
Huguette Casse
Huguette Casse
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Huguette Casse in
Google Scholar
PubMed
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Huguette Casse in
Google Scholar
PubMed
Sandra Fontanière
Sandra Fontanière
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Sandra Fontanière in
Google Scholar
PubMed
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Sandra Fontanière in
Google Scholar
PubMed
Anne-Marie Morera
Anne-Marie Morera
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Anne-Marie Morera in
Google Scholar
PubMed
Search for other papers by Anne-Marie Morera in
Google Scholar
PubMed
Séverine Mazaud Guittot
Séverine Mazaud Guittot
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Séverine Mazaud Guittot in
Google Scholar
PubMed
Search for other papers by Séverine Mazaud Guittot in
Google Scholar
PubMed
Alain Calender
Alain Calender
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Alain Calender in
Google Scholar
PubMed
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Alain Calender in
Google Scholar
PubMed
Nathalie Di Clemente
Nathalie Di Clemente
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Nathalie Di Clemente in
Google Scholar
PubMed
Search for other papers by Nathalie Di Clemente in
Google Scholar
PubMed
Chang X Zhang
Chang X Zhang
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Chang X Zhang in
Google Scholar
PubMed
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Université Claude Bernard Lyon, CNRS UMR5201, INSERM-INRA U418, INSERM, Groupe d'Etude Recherche, Lyon, France; Faculté de Médecine, Université Lyon 1, Lyon F-69003, France; Laboratoire Génétique Moléculaire, Signalisation et Cancer, 8 Avenue Rockefeller, Lyon F-69373, France
Search for other papers by Chang X Zhang in
Google Scholar
PubMed
. 2003 a ), using antibodies against menin (C19, 1:500), anti-p18 (1:3000), anti-p27 (1:1000), anti-pSmad1 (1:1000), anti-Smad1 (1:1000), anti-Smad3 (1:1000), anti-Smad4 (1:1000), anti-Smad5 polyclonal (1:1000) and anti-Cdk4 (1:1000, Santa
Tania Moujaber
Tania Moujaber
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Blacktown Cancer and Haematology Centre, Blacktown Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Tania Moujaber in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Blacktown Cancer and Haematology Centre, Blacktown Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Tania Moujaber in
Google Scholar
PubMed
Rosemary L Balleine
Rosemary L Balleine
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Children’s Medical Research Institute, Sydney, New South Wales, Australia
Search for other papers by Rosemary L Balleine in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Children’s Medical Research Institute, Sydney, New South Wales, Australia
Search for other papers by Rosemary L Balleine in
Google Scholar
PubMed
Bo Gao
Bo Gao
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Blacktown Cancer and Haematology Centre, Blacktown Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Bo Gao in
Google Scholar
PubMed
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Blacktown Cancer and Haematology Centre, Blacktown Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Bo Gao in
Google Scholar
PubMed
Ida Madsen
Ida Madsen
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Department of Gynaecological Oncology, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Ida Madsen in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Department of Gynaecological Oncology, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Ida Madsen in
Google Scholar
PubMed
Paul R Harnett
Paul R Harnett
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Paul R Harnett in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
Search for other papers by Paul R Harnett in
Google Scholar
PubMed
Anna DeFazio
Anna DeFazio
Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Department of Gynaecological Oncology, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, New South Wales, Australia
Search for other papers by Anna DeFazio in
Google Scholar
PubMed
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
Department of Gynaecological Oncology, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council New South Wales, Sydney, New South Wales, Australia
Search for other papers by Anna DeFazio in
Google Scholar
PubMed
turn activate MAPK/ERK kinase (MEK) 1/2 and then extracellular signal-regulated kinases (ERK1/2). ERK signalling causes increased cyclin D expression which activates cyclin-dependent kinases 4 and 6 (CDK4/6) and leads to increased cell proliferation
